Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10294792" target="_blank" >RIV/00216208:11110/15:10294792 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/15:10294792

Výsledek na webu

<a href="http://dx.doi.org/10.1002/ana.24339" target="_blank" >http://dx.doi.org/10.1002/ana.24339</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ana.24339" target="_blank" >10.1002/ana.24339</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Popis výsledku v původním jazyce

ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switchingto either of these agents. MethodsUsing MSBase, a large international, observational, prospectively acquired cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or disability progression within the 6 months immediately preceding switch to either natalizumab or fingolimod. Quasi-randomization with propensity score-based matching was used to select subpopulations with comparable baseline characteristics. Relapse and disability outcomes were compared in paired, pairwise-censored analyses. ResultsOf the 792 included patients, 578 patients were matched (natalizumab, n=407; fingolimod, n=171). Mean on-study follow-up was 12 months. The annualized relapse rates decreased from 1.5 to 0.2 on nat

Název v anglickém jazyce

Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis

Popis výsledku anglicky

ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly compared the outcomes of switchingto either of these agents. MethodsUsing MSBase, a large international, observational, prospectively acquired cohort study, we identified patients with relapsing-remitting multiple sclerosis experiencing relapses or disability progression within the 6 months immediately preceding switch to either natalizumab or fingolimod. Quasi-randomization with propensity score-based matching was used to select subpopulations with comparable baseline characteristics. Relapse and disability outcomes were compared in paired, pairwise-censored analyses. ResultsOf the 792 included patients, 578 patients were matched (natalizumab, n=407; fingolimod, n=171). Mean on-study follow-up was 12 months. The annualized relapse rates decreased from 1.5 to 0.2 on nat

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13237" target="_blank" >NT13237: Klinické a paraklinické markery roztroušené sklerózy – korelace se současným stavem pacienta a predikce průběhu nemoci.</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Neurology

ISSN

0364-5134

e-ISSN

—

Svazek periodika

77

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

425-435

Kód UT WoS článku

000350456800007

EID výsledku v databázi Scopus

2-s2.0-84923772724